Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference The new mini-textbook by Kamps & Hoffmann PDF, 110 pages

Lung Cancer

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 55 articles: HTML format Text format

Single Articles

February 2020
1. BERGHMANS T, Dingemans AM, Hendriks LEL, Cadranel J, et al
   Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm.
   Eur Respir J. 2020;55.
   PubMed     Text format    
   
   
   
2. KAUCZOR HU, Baird AM, Blum TG, Bonomo L, et al
   ESR/ERS statement paper on lung cancer screening.
   Eur Respir J. 2020;55.
   PubMed     Text format     Abstract available
   
   
   January 2020
3. HENDRIKS LEL, Cadranel J, Berghmans T
   Current challenges in the management of nonsmall cell lung cancer brain metastases.
   Eur Respir J. 2020;55.
   PubMed     Text format    
   
   
   November 2019
4. SUISSA S, Dell'Aniello S, Gonzalez AV, Ernst P, et al
   Inhaled corticosteroid use and the incidence of lung cancer in COPD.
   Eur Respir J. 2019 Nov 19. pii: 13993003.01720-2019.
   PubMed     Text format     Abstract available
   
   
   September 2019
5. SPIRO SG, Shah PL, Rintoul RC, George J, et al
   Sequential screening for lung cancer in a high-risk group: randomised controlled trial.
   Eur Respir J. 2019 Sep 19. pii: 13993003.00581-2019.
   PubMed     Text format     Abstract available
   
   
   
6. 
   "Screening for lung cancer: time for large-scale screening by chest computed tomography." Dekel Shlomi, Ronny Ben-Avi, Gingy Ronen Balmor, Amir Onn and Nir Peled. Eur Respir J 2014; 44: 217-238.
   Eur Respir J. 2019;54.
   PubMed     Text format    
   
   
   
7. SOLTANI A, Mahmood MQ, Reid DW, Walters EH, et al
   Cancer-protective effects of inhaled corticosteroids in COPD are likely related to modification of epithelial activation.
   Eur Respir J. 2019;54.
   PubMed     Text format    
   
   
   August 2019
8. OBERT M
   Are estimations of radiomic image markers dispensable due to recent deep learning findings?
   Eur Respir J. 2019;54.
   PubMed     Text format    
   
   
   July 2019
9. DENG HY, Zhou Q
   Lobectomy should remain the first choice for treating early stage nonsmall cell lung cancer.
   Eur Respir J. 2019;54.
   PubMed     Text format    
   
   
   
10. LU W, Sharma P, Eapen MS, Sohal SS, et al
    Inhaled corticosteroids attenuate epithelial mesenchymal transition: implications for COPD and lung cancer prophylaxis.
    Eur Respir J. 2019;54.
    PubMed     Text format    
    
    
    June 2019
11. SEIJO LM, Soriano JB, Peces-Barba G
    New evidence on the chemoprevention of inhaled steroids and the risk of lung cancer in COPD.
    Eur Respir J. 2019;53.
    PubMed     Text format    
    
    
    
12. BERZENJI L, Van Schil PE
    Surgery or stereotactic body radiotherapy for early-stage lung cancer: two sides of the same coin?
    Eur Respir J. 2019;53.
    PubMed     Text format    
    
    
    
13. KRISTOF AS, Ortega VE
    The discovery of novel mechanisms for lymphangioleiomyomatosis pathogenesis through GWAS: a rarity in rare respiratory disorders.
    Eur Respir J. 2019;53.
    PubMed     Text format    
    
    
    
14. AMAT B, Sapia S
    A journey to the centre of the mediastinal lymph nodes.
    Eur Respir J. 2019;53.
    PubMed     Text format    
    
    
    May 2019
15. GRACIE K, Kennedy MPT, Esterbrook G, Smith G, et al
    The proportion of lung cancer patients attending UK lung cancer clinics who would have been eligible for low-dose CT screening.
    Eur Respir J. 2019 May 16. pii: 13993003.02221-2018.
    PubMed     Text format    
    
    
    April 2019
16. WIJMANS L, Yared J, de Bruin DM, Meijer SL, et al
    Needle-based confocal laser endomicroscopy (nCLE) for real-time diagnosing and staging of lung cancer.
    Eur Respir J. 2019 Apr 25. pii: 13993003.01520-2018.
    PubMed     Text format     Abstract available
    
    
    
17. RAYMAKERS AJN, Sadatsafavi M, Sin DD, FitzGerald JM, et al
    Inhaled corticosteroids and the risk of lung cancer in chronic obstructive pulmonary disease (COPD): a population-based cohort study.
    Eur Respir J. 2019 Apr 7. pii: 13993003.01257-2018.
    PubMed     Text format     Abstract available
    
    
    March 2019
18. DETILLON DEMA, Aarts MJ, De Jaeger K, Van Eijck CHJ, et al
    Video-assisted thoracic lobectomy versus stereotactic body radiotherapy for stage I non-small cell lung cancer in elderly patients: a propensity matched comparative analysis.
    Eur Respir J. 2019 Mar 28. pii: 13993003.01561-2018.
    PubMed     Text format     Abstract available
    
    
    February 2019
19. CASAL RF, Sepesi B, Sagar AS, Tschirren J, et al
    Centrally-located lung cancer and risk of occult nodal disease: an objective evaluation of multiple definitions of tumor centrality with a dedicated imaging software.
    Eur Respir J. 2019 Feb 28. pii: 13993003.02220-2018.
    PubMed     Text format     Abstract available
    
    
    January 2019
20. SPENCER KL, Kennedy MPT, Lummis KL, Ellames DAB, et al
    Surgery or radiotherapy for stage I lung cancer? An intention to treat analysis.
    Eur Respir J. 2019 Jan 11. pii: 13993003.01568-2018.
    PubMed     Text format     Abstract available
    
    
    
21. SHIN SH, Jeong DY, Lee KS, Cho JH, et al
    Which definition of central tumour is more predictive of occult mediastinal metastasis in non-small cell lung cancer patients with radiologic N0 disease?
    Eur Respir J. 2019 Jan 11. pii: 13993003.01508-2018.
    PubMed     Text format     Abstract available
    
    
    December 2018
22. LU J, Zhong H, Chu T, Zhang X, et al
    Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy.
    Eur Respir J. 2018 Dec 21. pii: 13993003.01562-2018.
    PubMed     Text format     Abstract available
    
    
    
23. CROMBAG LMM, Dooms C, Stigt JA, Tournoy KG, et al
    Systematic and combined endosonographic staging of lung cancer (SCORE Study).
    Eur Respir J. 2018 Dec 21. pii: 13993003.00800-2018.
    PubMed     Text format     Abstract available
    
    
    October 2018
24. RICH AL, Baldwin DR, Beckett P, Berghmans T, et al
    ERS Statement on harmonised standards for lung cancer registration and lung cancer services in Europe.
    Eur Respir J. 2018 Oct 25. pii: 13993003.00610-2018.
    PubMed     Text format     Abstract available
    
    
    September 2018
25. MEYER G, Besse B, Doubre H, Charles-Nelson A, et al
    Antitumor Effect of Low Molecular Weight Heparin in Localised Lung Cancer A Phase III Clinical Trial.
    Eur Respir J. 2018 Sep 27. pii: 13993003.01220-2018.
    PubMed     Text format     Abstract available
    
    
    August 2018
26. VISSER S, Huisbrink J, van 't Veer NE, van Toor JJ, et al
    Renal impairment during pemetrexed maintenance in patients with advanced non-small-cell lung cancer: a cohort study.
    Eur Respir J. 2018 Aug 23. pii: 13993003.00884-2018.
    PubMed     Text format     Abstract available
    
    
    
27. VOLLMER I, Sanchez M, Rami-Porta R
    Lung cancer staging: imagine fewer images.
    Eur Respir J. 2018;52.
    PubMed     Text format    
    
    
    
28. TOURNOY KG, Van Meerbeeck JP
    Lung cancer staging: imagine fewer images.
    Eur Respir J. 2018;52.
    PubMed     Text format    
    
    
    June 2018
29. LOUBIERE S, Barlesi F, Missy P, Morin F, et al
    Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times.
    Eur Respir J. 2018;51.
    PubMed     Text format    
    
    
    
30. UGUEN A
    Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times.
    Eur Respir J. 2018;51.
    PubMed     Text format    
    
    
    
31. MASSARD G, Tabin N, Mitchell S, Batirel H, et al
    A harmonised European training syllabus for thoracic surgery: report from the ESTS/ERS task force group.
    Eur Respir J. 2018;51.
    PubMed     Text format    
    
    
    
32. KURMI OP
    Is low level of vitamin D a marker of poor health, or a cause?
    Eur Respir J. 2018;51.
    PubMed     Text format    
    
    
    May 2018
33. MIKESCH JH, Schwammbach D, Hartmann W, Schmidt LH, et al
    Reptin drives tumour progression and resistance to chemotherapy in non-small cell lung cancer.
    Eur Respir J. 2018 May 31. pii: 13993003.01637-2017.
    PubMed     Text format     Abstract available
    
    
    
34. SANDRI BJ, Kaplan A, Hodgson SW, Peterson M, et al
    Multi-Omic Molecular Profiling of Lung Cancer in Chronic Obstructive Pulmonary Disease.
    Eur Respir J. 2018 May 24. pii: 13993003.02665-2017.
    PubMed     Text format     Abstract available
    
    
    
35. SUN YQ, Brumpton BM, Bonilla C, Lewis SJ, et al
    Serum 25-hydroxyvitamin D levels and risk of lung cancer and histologic types: a Mendelian randomisation analysis of the HUNT study.
    Eur Respir J. 2018 May 10. pii: 13993003.00329-2018.
    PubMed     Text format     Abstract available
    
    
    
36. SCHEERENS C, Beernaert K, Pype P, Cohen J, et al
    Comparing the use and timing of palliative care services in COPD and lung cancer: a population-based survey.
    Eur Respir J. 2018;51.
    PubMed     Text format    
    
    
    
37. VAN MEERBEECK JP, Jansen G, Giovannetti E, Peters GJ, et al
    Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks.
    Eur Respir J. 2018;51.
    PubMed     Text format    
    
    
    April 2018
38. RAMI-PORTA R, Call S, Dooms C, Obiols C, et al
    Lung cancer staging: a concise update.
    Eur Respir J. 2018 Apr 26. pii: 13993003.00190-2018.
    PubMed     Text format     Abstract available
    
    
    
39. DECALUWE H, Dooms C, De Leyn P, Thomas P, et al
    Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease.
    Eur Respir J. 2018;51.
    PubMed     Text format    
    
    
    
40. ADDEO A, Banna G
    Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease.
    Eur Respir J. 2018;51.
    PubMed     Text format    
    
    
    March 2018
41. ZUGAZAGOITIA J, Biosca M, Olivera J, Eugenia Olmedo M, et al
    Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small-cell lung cancer.
    Eur Respir J. 2018 Mar 21. pii: 13993003.02431-2017.
    PubMed     Text format    
    
    
    
42. LOUBIERE S, Drezet A, Beau-Faller M, Moro-Sibilot D, et al
    Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available
    
    
    
43. UGUEN M, Dewitte JD, Lodde B, Marcorelles P, et al
    Asbestos-related lung cancers are rarely associated with ALK, ROS1 and RET rearrangements.
    Eur Respir J. 2018;51.
    PubMed     Text format    
    
    
    December 2017
44. DECALUWE H, Dooms C, D'Journo XB, Call S, et al
    Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available
    
    
    October 2017
45. SUN YQ, Chen Y, Langhammer A, Skorpen F, et al
    Passive smoking in relation to lung cancer incidence and histologic types in Norwegian adults: the HUNT study.
    Eur Respir J. 2017;50.
    PubMed     Text format    
    
    
    
46. PARIS C, Do P, Mastroianni B, Dixmier A, et al
    Association between lung cancer somatic mutations and occupational exposure in never-smokers.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available
    
    
    August 2017
47. TOMASINI P, Brosseau S, Mazieres J, Merlio JP, et al
    EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available
    
    
    
48. GLATZER M, Rittmeyer A, Muller J, Opitz I, et al
    Treatment of limited disease small cell lung cancer: the multidisciplinary team.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available
    
    
    July 2017
49. PLUVY J, Brosseau S, Naltet C, Opsomer MA, et al
    Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment.
    Eur Respir J. 2017;50.
    PubMed     Text format    
    
    
    May 2017
50. AAMLI GAGNAT A, Gjerdevik M, Gallefoss F, Coxson HO, et al
    Incidence of non-pulmonary cancer and lung cancer by amount of emphysema and airway wall thickness: a community-based cohort.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available
    
    
    April 2017
51. TIAN Q, Deng WJ, Li ZW
    Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient.
    Eur Respir J. 2017;49.
    PubMed     Text format    
    
    
    
52. KHIROYA H, Moore JS, Ahmad N, Kay J, et al
    IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available
    
    
    
53. CALVAYRAC O, Pradines A, Pons E, Mazieres J, et al
    Molecular biomarkers for lung adenocarcinoma.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available
    
    
    March 2017
54. LEDUC C, Antoni D, Charloux A, Falcoz PE, et al
    Comorbidities in the management of patients with lung cancer.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available
    
    
    
55. DE PERROT M, Dong Z, Bradbury P, Patsios D, et al
    Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: